Physician profile
Robert B Constant
NPI 1124039458
$6,628.41
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,252 · 2020: $2,593 · 2021: $1,350 · 2022: $417 · 2023: $16.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $1,507.28 | 2019-2020 | |
| Tosoh Bioscience, INC. | $1,121.00 | 2019 | |
| Novo Nordisk INC | $675.23 | 2019-2022 | |
| Amgen INC. | $276.22 | 2019-2023 | Prolia, Evenity |
| Abbvie INC. | $236.48 | 2019-2021 | |
| Radius Health, INC. | $214.56 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.31 | 2019-2022 | |
| Abbott Laboratories | $187.06 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.20 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $171.59 | 2020-2021 | |
| Ibsa Pharma INC. | $168.40 | 2019-2022 | |
| Horizon Therapeutics Plc | $160.64 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $138.50 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $121.67 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $120.70 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $117.65 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $93.79 | 2020-2022 | |
| Dexcom, INC. | $89.06 | 2021-2022 | |
| Insulet Corporation | $79.60 | 2019-2020 | |
| Medtronic, INC. | $78.19 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $72.51 | 2019-2022 | |
| Shire North American Group INC | $70.88 | 2019 | |
| Antares Pharma, INC. | $69.12 | 2019-2021 | |
| Lifescan, INC. | $56.02 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $51.20 | 2019-2020 | |
| Corcept Therapeutics | $45.34 | 2020-2021 | |
| Zealand Pharma US, INC. | $45.24 | 2021 | |
| Mannkind Corporation | $43.24 | 2019 | |
| Pfizer INC. | $35.28 | 2019-2020 | |
| Grt US Holding, INC. | $34.67 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $33.04 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $32.74 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.44 | 2019 | |
| Recordati_rare_diseases_inc. | $19.00 | 2020 | |
| Roche Diabetes Care, INC. | $17.08 | 2020 | |
| Amarin Pharma, INC. | $15.23 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.68 | 2019 | |
| Vistapharm, INC. | $12.82 | 2021 | |
| Clarus Therapeutics INC. | $5.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Constant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.